[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526359":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":39,"centralContacts":44,"locations":51,"responsibleParty":80,"collaborators":49,"id":83,"slug":49,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":49,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":49,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":49,"overallStatus":54,"whyStopped":49,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine","ACTIVE_COMPARATOR","Patients will receive injection of 1 microgram\u002Fkg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve",[13],"Drug: Dexmedetomidine",{"label":15,"type":10,"description":16,"interventionNames":17},"Ozone","Participants will receive a single local injection of 4 ml ozone (10 micrograms\u002Fml) plus to 1 ml lidocaine (1%) using a 25 G needle.",[18],"Drug: Ozone",{"label":20,"type":10,"description":21,"interventionNames":22},"Dexamethasone","Patients will receive a single local injection of 5 mL (3 mL lidocaine (1%) and 2 mL \\[8 mg\\] dexamethasone) via the same technique.",[23],"Drug: Dexamethasone",[25,31,35],{"type":26,"name":9,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Patients will receive injection of 1 microgram\u002Fkg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve.",[9],[30],"Precedex®",{"type":26,"name":15,"description":16,"armGroupLabels":32,"otherNames":33},[15],[34],"PubChem CID 24823",{"type":26,"name":20,"description":21,"armGroupLabels":36,"otherNames":37},[20],[38],"Decadron",[40],{"name":41,"affiliation":42,"role":43},"MAHMOUD ELGEBALY, MD","Tanta faculty of medicine","PRINCIPAL_INVESTIGATOR",[45],{"name":46,"role":47,"phone":48,"phoneExt":49,"email":50},"Mahmoud T Elgebaly, MD","CONTACT","00201092415231",null,"mahmoud.talaat@med.tanta.edu",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Faculty of Medicine","RECRUITING","Tanta","El Gharbia","31527","Egypt",{"type":60,"coordinates":61},"Point",[62,63],31.00192,30.78847,{"lat":63,"lon":62},[66,68,71,74,76,78],{"name":67,"role":47,"phone":48,"phoneExt":49,"email":50},"Mahmoud Elgebaly, MD",{"name":67,"role":47,"phone":69,"phoneExt":49,"email":70},"00201006145708","mahmoudelgebaly75@gmail.com",{"name":72,"role":73,"phone":49,"phoneExt":49,"email":49},"Ayman A yousef, MD","SUB_INVESTIGATOR",{"name":75,"role":73,"phone":49,"phoneExt":49,"email":49},"Ashraf A Abo Elsafa, MD",{"name":77,"role":73,"phone":49,"phoneExt":49,"email":49},"Ahmed E Salim, MD",{"name":79,"role":73,"phone":49,"phoneExt":49,"email":49},"Alaa M Abo Hagar, MD",{"type":43,"investigatorFullName":81,"investigatorTitle":82,"investigatorAffiliation":5,"oldNameTitle":49,"oldOrganization":49},"Mahmoud T Elgebaly,MD","Assistant Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine","100526359",false,"NCT06133712","Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Pain Relief","A Comparative Study Between Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Long- Term Pain Relief","Inclusion Criteria:\n\n* Age from 20 to 60 years.\n* Both sexes.\n* Patients with ultrasonographic evidence of mild-to-moderate carpal tunnel syndrome (CTS).\n* Inclusion criteria will include numbness and pain in the median nerve (MN) distribution persisting for minimum of 3 months , nerve conduction studies (NCS) consistent with carpal tunnel syndrome (CTS) as per the American Association of Neuromuscular and Electro diagnostic Medicine (AANEM) guidelines, and an median nerve (MN) cross-sectional area (CSA)at the wrist \\>12 mm2 suggesting mild-to-moderate CTS forms.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Patients with severe symptoms and signs of CTS as identified per the American Association of Neuromuscular and Electro diagnostic Medicine (AANEM) guidelines,\\[14\\] as this is an indication for surgery,\n* Patients who show improvement on medical treatment,\n* Previous surgical or injectional CTS treatment,\n* Pregnancy ,co existence of brachial plexopathy, or thoracic outlet syndrome, polyneuropathy, radiculopathy and peripheral nerve lesion in upper limb.\n* Severe cardiovascular disease\n* Morbid obese patients (body mass index (BMI) of \\>35 kg\u002Fm2)\n* Infection at site of injection.\n* Bleeding diathesis.\n* History of thyroid deficiency, uncontrolled diabetes mellitus , rheumatoid arthritis and history of glucose-6-phosphate dehydrogenase (G6PD) deficiency\n* History of Ozone or Dexmedetomidine allergy.\n* End stage renal and hepatic disease.\n* History of inflammatory joint , connective tissue disorders, , burns, any local tissue contractures and history of wrist trauma.\n* Patients who will not consent to completing The visual analogue scale (VAS) for pain or nerve conduction study before and after injection.","ALL","20 Years","60 Years",{"count":93,"type":94},135,"ESTIMATED","INTERVENTIONAL",[97],"NA","The aim of the present study is to compare the analgesic efficacy of Dexmedetomidine, Ozone and Dexamethasone regional injection in carpal tunnel syndrome.",[100,9,15,20],"Carpal Tunnel","2025-05-22",{"date":103,"type":104},"2025-05-29","ACTUAL",{"date":106,"type":104},"2023-11-01",{"date":108,"type":94},"2025-12-01",{"name":5,"class":6},1]